WebFilings | EDGAR view
 

 
 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
__________________
 
FORM 8-K
__________________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported):    April 28, 2011
 
 
Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
000-30111
76-0474169
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
 
 
8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive
offices and Zip Code)
 
 
(281) 863-3000
(Registrant's telephone number,
including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 

 

 

 
Item 5.07    Submission of Matters to a Vote of Security Holders
 
Our annual meeting of stockholders was held on April 28, 2011 to consider and vote on the following proposals. The voting results with respect to each matter are set forth below:
(1)
Election of Class II Directors:
 
 
 
 
Name of Director
For
Withheld
Broker Non-Votes
 
Samuel L. Barker, Ph.D.
275,620,416
2,268,924
38,376,326
 
Christopher J. Sobecki
258,704,702
19,184,638
38,376,326
 
Judith L. Swain, M.D.
275,416,535
2,472,805
38,376,326
 
 
 
 
For
Against
Abstain
Broker Non-Votes
(2)
Advisory vote on the compensation paid to our named executive officers
218,152,121
52,252,078
7,485,141
38,376,326
 
 
 
 
1 Year
2 Years
3 Years
Abstain
Broker Non-Votes
(3)
Advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers
257,862,309
128,024
12,425,685
7,473,322
 
 
 
 
For
Against
Abstain
Broker Non-Votes
(4)
Ratification and approval of the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2011
315,712,100
411,574
141,992
 
 
 

 

 

 
 
 
Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Lexicon Pharmaceuticals, Inc.
 
 
 
 
 
 
Date: April 29, 2011
By:
/s/ Brian T. Crum
 
 
Brian T. Crum
 
 
Vice President and General Counsel